thank you joining. Good morning everyone and for
view in strategy. of COVID-XX our We extraordinary perspective we the the markets and of we on on and our strength impact effectiveness give the will our pandemic our the provide and of of times continue today, performance will live to
prioritized remain to business service preservation all allowing to and to crisis pandemic-related for We manufacturing, and of safety, to supply operational lines. our of continuity, our chose across cash We fully all our Our stockouts against response safeguard disruptions. customer prepare build inventory chain, recovery. in avoid product and to markets
our through-cycle our track. kept approach turnaround on Importantly,
laying are as continued foundation for executing We planned and the growth.
For recently spite example, in of our all completed the showed annual survey exceptionally we circumstances. and morale third challenging results strong employee
Our are drivers us recovery and the value intact propel new will through and normal.
see few minutes. and talk a provide me highlights. will attractive challenges, significant remain markets about Let how marketplace them hospital we with I in current recovering a plasma growth potential. few Despite
We digitization. management are making meaningful progress platform software hemostasis NexSys on with development and programs, and our innovation agenda clinical advancements,
Pittsburgh a We excellence sourcing program. strategic hospital to new plasma into select year and are investments and including site four-year like pursuing remain a optimization U.S. on network support disposables. lean operational We our schedule
Our growth-oriented transactions and our recently announced show M&A. intent ability to execute
technologies to augmenting is continue adapt the important COVID-XX to growth the cash to providers, customers' fully with donors, our on timing and and to leveraging we healthcare, effects prioritize trajectory. crisis our balance free investments, committed are well We recover and the patients. our response pandemic the XXXX. pre to expect expect and The of uncertain based is through fiscal allocating capital flow. We pruning thrive and growth to to and Haemonetics to strong positioned sheet portfolio bringing and levels end
revenue public the the North XX% a of year. throughout increase. main border plasma donate. fiscal collection reported orders organic and quarter with the XXXX in travel driver Factors influencing Let's to XX% the quarter, and decline campus American reticence due blood to pandemic limited revenue in prior to per hospital closures as revenue was negatively collections XX%. Plasma college and share our primarily of adjusted decrease in XX% declined results. first declines Today, the of The quarter revenue turn transportation included the and volumes we as a earnings by stay-at-home well decrease compared center
quarter lifted. As the stay-at-home were progressed orders
were was and plasma well the precautions for continued donations Social need publicized. established distancing
However, with software lower in the in volumes a collection of Along quarter pandemic, collection persisted. volumes depressed to one-time have the decreased due benefit XXXX. fiscal because revenue
cloud-based manage Our created home our track continues collections collaboration incremental distancing remote and at XX We through work The convert and have R&D platform technical a challenges. plasma. efficiency, customers with to YES help streamline to safety, pre-collection version on support NexSys support. we shifted of remains deliver resources to enabling implementation value deployed XXXXXX register to software the of NexLynk latest to and to rapidly as seamlessly convenience. million enhanced leaders donors the customers social application process yielding
are assessing plasma. more We and the expanded of data biometric donations including use to innovation donor advancing personalized to analytics safely collect meaningful
excitement the market customers and in pandemic. volume recovery. to of collection need will is about historic has our accelerate as to We collections to of uncertain current unique environment role anticipate plasma medicines our we the plasma agent will a rates. and underlying a timing changed plasma the end as plasma's There replenish that protracted The inventory. the collection The therapeutic volume depleted on for expect improve While we fully the demand challenge plasma-derived remain strength exact to the of growth growth not virus. is for is return about also a confident growing based treatment potential part
X% are are important over approval for to potential robust the in prospects pricing commercial plasma to believe segment, within possible for to and there autoimmune avoid entrants of is but and in disorders. volume more there collection Meanwhile to for and relative trials aware hurdles drugs. XX% new to market deficiency there questions growth reducing room our continue plasma-derived to help do to a thousands to treatment immune will We the primary addition benefits of FcRn are scalability. term, materially autoimmune the underway customers allow new like of utility clinical about clinical supply without the create We time. disruption new alternatives normal everything Longer we
resources to related the comparator restrictions calendar began pandemic's XXXX quarter quarter for in a ICU felt procedure was recovery as impact the fiscal XX% with in teams. COVID-XX declines, Moving during in U.S. impact resume fourth restricted grew China hospitals compared to earlier with to to by approximately sales The access the primarily and declined China quarter quarter in prior China Hospital. hospital to being needs mostly markets of both year. Revenue the and America and some X% diverted due due lower caused critical eased procedures. North the in sequentially from the
in quarter fiscal down primarily and the occurred the and against combination due selling was fourth in XX% year North distributor record our patients. due sales prior strong still to capital U.K., well quarter America. revenue to Hemostasis due COVID-XX to quarter to was first primarily XXXX activity timing. the in The was in hospitals up revenue a order research that quarter management However, of sales to COVID-XX Italy as of high-volume capital as sales coagulation X%
delivered recover reopened of our North quarter disposable offset the Our of double-digit lower on to America. hospital largest market. declines to economy capital in China which volume the due as sales, increased started Disposable helped and in TEG business European to usage revenues U.S. the second and in procedure the procedure strength half growth volume
lower to revenue points able in added from been our ClotPro had While in from our SafeTrace the as was which as we ability basis quarter we for XXXX revenue by successfully XX to due in salvage our down up on Cell several hospitals to that rate America volumes. procedure Transfusion in reported to growth was BloodTrack organic access during rate, the hospitals acquired April in quarter Italy fiscal partially were perform Tx new first impacted to not pipeline. primarily quarter management XX% was growth BloodTrack X% growth North U.K., and primarily to quarter. the deals declines fourth offset due revenue included growth strong first in the close installations. limited significantly
elective current the addition other not distancing salvage hospital, so quarter. procedures procedures, global sensitive during suspended non-elective participate in of of Unlike significantly various of level billion social remains areas we related see is business strong. declined is quarter. areas underpenetrated. the lockdowns and declines a first It Despite In fast-growing procedure all in believe trauma We trajectory and Hospital $X and challenges, long-term cardiology we this largely the during the due to to to same more incidents cell critical recovery still did opportunity the like is that trauma.
levels. capital hospitals procedure continue development regions robust The watching strengthen transfusion and and non-elective continue these TEG, products benefit term, in XX% and closely we are be end the procedures Elective China, resurgences these in a pipeline to North to presence are We near particularly approaches to the as to to our In from management. for ClotPro we return revenue. pre-COVID differently and will in go-to-market in constraints. individual impacted will making normalize comprise hospital will we America volumes will demand our and market developments associated by of have which improvements vary and impact
Our normal of such that the hospital in customers will return expect levels our the we procedure are navigating call by I'll to business. these about turn blood sequential challenges over our with who now, year. end to And center talk fiscal a Chad volumes quarter-over-quarter improvement
